Dave Dixon, PharmD, FACC, FAHA, FCCP, FNLA, BCACP, CLS

Dave Dixon, PharmD, examines why SGLT2 inhibitor and GLP-1 uptake remain low and how pharmacists can bridge the gap between evidence and implementation.

Dave Dixon, PharmD, breaks down the key cardiovascular and kidney risk management updates in the 2026 ADA Standards of Care and what they mean for pharmacy practice.

Pharmacists' role in lipid management takes center stage with the 2026 dyslipidemia guideline update.